Cyberonics — Merger or Acquisition (June 2015)
17 slides from Cyberonics's merger presentation, Jun 17, 2015
Slide 1: Creating a Premier Global Medical Technology Company
REATING A PREMIER GLOBAL MEDICAL TECHNOLOGY COMPANY
Slide 2: Disclaimer / Safe Harbor Statement
Disclaimer / Safe Harbor Statement Important Information for Investors and Shareholders This presentation is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscri
Slide 3: Sorin Group and Cyberonics to create a leading global medical technology company
Sorin Group and Cyberonics Inc. to create a leading global medical technology company Diverse, market-leading product portfolio to drive shareholder value Technical and commercial scale across geographies to enhance revenue growth Focused innovation platform to exploit market opportunities and accel
Slide 4: Compelling strategic rationale
Compelling strategic rationale Opportunities in Three Global Scale and Leadership in Large and Multi-Billion Dollar Geographic Growing Markets Specialty Markets Diversification Highly Complementary Strong Balance Sheet to Technologies Execute Plan 4
Slide 5: Cyberonics and Sorin at a glance
Cyberonics and Sorin at a glance Revenues1 $292m $998m Manufacturing Facilities 2 10 Employees ~650 ~3,900 Market ? Leader in devices for epilepsy and ? Global leader in Cardiac Surgery and Leadership neuromodulation pioneer leading innovator in CRM Neuromodulation Failure (HF) ? Sutureless valve (P
Slide 6: Global scale and geographical diversification
Global scale and geographical diversification Louvain-la-Neuve, Belgium Suzhou, China Denver, CO Saluggia, Italy Brussels Clamart, France Vancouver, BC Munich, Germany Meylan, Dominican France Republic Mirandola, Italy Houston, TX Cantù, Italy Costa Rica Joint venture, China Cyberonics Manufacturing
Slide 7: Highly complementary businesses
Highly complementary businesses … Business Unit Geography Neuromodulation International 100% 19% Revenues1: $292m US 81% CRM US 33% 23% Revenues1 : $998m Cardiac International Surgery 77% 67% 1) FY 2015 figures as of April 24th 2015 for Cyberonics. FY 2014 figures as of 31st December 2014 for Sorin
Slide 8: Diversified product portfolio and broader geographical reach
.leading to diversified product portfolio and broader geographical reach Pro forma revenues by geography1 Pro forma revenues by business1 Neuromodulation Rest of 23% World 21% Europe 43% Cardiac $1.3bn $1.3bn Surgery 52% US CRM 36% 25% 1) FY 2015 figures as of April 24th 2015 for Cyberonics. FY 2014
Slide 9: Leadership in large and growing markets
Leadership in large and growing markets Bringing together global leaders in Cardiac Surgery and Neuromodulation Leveraging an innovative Cardiac Rhythm Management platform CARDIAC NEUROMODULATION CRM SURGERY Cardiopulmonary global Long-standing leader in Leading innovator in CRM leader Neuromodulati
Slide 10: Highly complementary technologies and selling capabilities
Highly complementary technologies and selling capabilities Shared technologies Complementary commercialization capabilities Implantable electronics Market development skills Patient awareness & physician Heart Failure Neuromodulation education VNS Science Epileptologists and Expertise Wireless Neuro
Slide 11: Opportunities in billion dollar specialty markets
Opportunities in billion dollar specialty markets Accelerated development and commercialization of new product categories The combined opportunities leverage Cyberonics’ ability to develop markets and Sorin’s geographical reach Heart Failure (HF) Sleep Apnea Percutaneous Mitral Potential market oppo
Slide 12: Operating synergies driving significant incremental value
Operating synergies driving significant incremental value Heart failure Capitalizing on market relationships with wider product range Neuromodulation revenue Cyberonics’ leverage of Sorin’s commercialization network Manufacturing Purchasing savings and improved manufacturing overhead utilization Opt
Slide 13: Experienced, world-class management team
Experienced, world-class management team André-Michel Ballester Dan Moore Chief Executive Officer Non-Executive Chairman of the Board Michel Darnaud Stefano Di Lullo Rohan Hoare Jacques Gutedel Head of Cardiac Head of Cardiac Head of Head of Surgery Rhythm Management Neuromodulation Intercontinental
Slide 14: Transaction overview
Transaction overview HoldCo Domicile and listing Exchange ratio Incorporated in the UK and UK tax 1:1 of HoldCo stock for Cyberonics resident shareholders Dual listed on Nasdaq and London Stock 0.0472:1 of HoldCo stock for Sorin Exchange shareholders Ownership Governance Cyberonics shareholders: ~ 5
Slide 15: Transaction timeline: closing expected by end of September 2015
Transaction timeline: closing expected by end of September 2015 Key milestones achieved Next steps Unanimous approval by BoD and deal announcement End of 60-day Sorin Creditor Rights period 26 Feb 27 July Cyberonics stockholders meeting (at least 20 US Antitrust approval business days after S-4 Form
Slide 16: Driving significant shareholder returns
Driving significant shareholder returns Stronger and more diversified platform for growth Revenue growth • Significant revenue potential from highly complementary Heart acceleration Failure programs Leverage Sorin’s commercialization network for Neuromodulation Approximately $80 million annual pre-t
Slide 17: Contacts
Contacts FOR SORIN GROUP: FOR CYBERONICS, INC.: Investors: Investors: Demetrio Mauro Greg Browne CFO CFO Sorin Group Cyberonics, Inc. Tel: +39 02 69969 512 Tel: +1 281 228 7262 e-mail: [email protected] e-mail: [email protected] Francesca Rambaudi Media: Director, Investor Relations Sorin